SELLAS Life Sciences Secures $31 Million Through Warrant Exercise to Advance Cancer Therapeutics Pipeline
核心洞察
SELLAS Life Sciences announced the immediate exercise of warrants for approximately $31 million in gross proceeds to fund its late-stage cancer (搜索) therapy development programs.
The company is developing GPS, a WT1-targeting therapy licensed from Memorial Sloan Kettering, and SLS009, a potentially first-in-class CDK9 (搜索) inhibitor for acute myeloid leukemia (搜索).
SELLAS will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders to discuss unmet medical needs in acute myeloid leukemia (搜索) treatment.
SELLAS Life Sciences Group, Inc. announced on October 27, 2025, the immediate exercise of warrants to purchase up to 22,363,714 shares of common stock, generating approximately $31.0 million in gross cash proceeds. The warrants were previously issued in March and August 2024, with the transaction expected to close on October 28, 2025.
Financial Structure and New Warrant Issuance
In consideration for the immediate exercise of the existing warrants, the investor will receive new registered warrants to purchase up to 22,363,714 shares of common stock at an exercise price of $2.00. These new warrants will be exercisable immediately and expire five years from the date of issuance. A.G.P./Alliance Global Partners (搜索) and Maxim Group LLC (搜索) served as financial advisors for the transaction.
Pipeline Development Focus
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for a broad range of cancer (搜索) indications. The company's lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein (搜索), which is present in an array of tumor types. GPS has potential as both a monotherapy and in combination with other therapies to address a broad spectrum of hematologic malignancies (搜索) and solid tumor (搜索) indications.
CDK9 Inhibitor Shows Promise in AML
The company is also developing SLS009 (tambiciclib), described as potentially the first and best-in-class differentiated small molecule CDK9 (搜索) inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML (搜索) patients with unfavorable prognostic factors including ASXL1 (搜索) mutation, commonly associated with poor prognosis in various myeloid diseases (搜索).
Upcoming R&D Day Event
SELLAS will host a virtual R&D Day on Wednesday, October 29, 2025 at 10:00 AM ET, featuring key opinion leaders alongside company management to discuss the unmet medical need and evolving treatment landscape for acute myeloid leukemia (搜索). The event aims to provide insights into the company's therapeutic approach and market positioning.
Regulatory and Market Positioning
The shares of common stock issuable upon exercise of the existing warrants have been registered pursuant to effective registration statements on Form S-3. The offering is being made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission, providing regulatory clarity for the transaction structure.